- Home
- ACTU vs SCPH Comparison
ACTU vs SCPH Comparison
Compare ACTU & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- SCPH
- Stock Information
- Founded
- ACTU 2015
- SCPH 2013
- Country
- ACTU United States
- SCPH United States
- Employees
- ACTU N/A
- SCPH N/A
- Industry
- ACTU
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- ACTU
- SCPH Health Care
- Exchange
- ACTU NYSE
- SCPH Nasdaq
- Market Cap
- ACTU 162.1M
- SCPH 173.6M
- IPO Year
- ACTU 2024
- SCPH 2017
- Fundamental
- Price
- ACTU $7.69
- SCPH $3.25
- Analyst Decision
- ACTU
- SCPH Strong Buy
- Analyst Count
- ACTU 0
- SCPH 2
- Target Price
- ACTU N/A
- SCPH $15.00
- AVG Volume (30 Days)
- ACTU 20.8K
- SCPH 267.8K
- Earning Date
- ACTU 03-04-2025
- SCPH 03-12-2025
- Dividend Yield
- ACTU N/A
- SCPH N/A
- EPS Growth
- ACTU N/A
- SCPH N/A
- EPS
- ACTU N/A
- SCPH N/A
- Revenue
- ACTU N/A
- SCPH $30,278,000.00
- Revenue This Year
- ACTU N/A
- SCPH $172.27
- Revenue Next Year
- ACTU N/A
- SCPH $131.75
- P/E Ratio
- ACTU N/A
- SCPH N/A
- Revenue Growth
- ACTU N/A
- SCPH 303.87
- 52 Week Low
- ACTU $5.51
- SCPH $3.08
- 52 Week High
- ACTU $11.73
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- SCPH 43.27
- Support Level
- ACTU N/A
- SCPH $3.09
- Resistance Level
- ACTU N/A
- SCPH $3.87
- Average True Range (ATR)
- ACTU 0.00
- SCPH 0.20
- MACD
- ACTU 0.00
- SCPH 0.00
- Stochastic Oscillator
- ACTU 0.00
- SCPH 20.65
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.